

Menini C, Moretti M, Fabbri L, Carillo C, **Ravagnani F**. **Valutazione costo-benefici fra alcuni metodi per la prevenzione dell'HBV nella pratica trasfusionale**. Arcispedale S.Anna, Vol. XXXIII, Suppl. 4, 1983.

Balsari A, Fossati G, Taramelli D, Nava M, **Ravagnani F**. **Inhibition of human melanoma growth in nude mice by autologous, alloactivated peripheral blood lymphocytes**. Tumori, 70: 35-39, 1984.

**Sciorelli G, Ravagnani F, and Pellegris G**. **Granulocyte transfusion therapy**. Int J Artif Organs, Vol 7, N° 6: 353-356, 1984.

**Ravagnani F, Sciorelli G**, Marconi M, Fornasari PM. **Problematica ed assistenza psicologica al donatore**. Boll Agg di Emaferesi, 1: 210-218, 1985.

**Sciorelli G, Ravagnani F**, Gambacorti Passerini C, Balsari A, Belli F, Marolda R, and **Pellegris G**. **Transfusion of autologous, alloactivated helper-enriched lymphocytes obtained by cytopheresis to patients with melanoma**. Plasma Ther Transfu Technol, 7:469-476, 1986.

**C.Lombardo**, C.Agazzi, Mt.Illeni."Frequenza dei geni HLA nella popolazione Lombarda". T.d.S.,21,1986.

Taramelli D., Fossati G., **Mazzocchi A.**, Delia D., Ferrone S., Parmiani G.: **Classes I and II HLA and melanoma-associated antigen expression and modulation on melanoma cells isolated from primary and metastatic lesions**. *Cancer Res*. 46: 433-439, 1986.

L.Salvaneschi, M.Martinetti, M.Cuccia Belvedere, G.Pellegris, **C.Lombardo**, M.T.Illeni."Die Klinische Bedeutung des Human-Lymphozytenantigens HLA". Laboratorium Medizin 12,390,1986.

M.T.Illeni, R.Doci, E.Mascheretti, C.Agazzi, **C.Lombardo**, R.A.Audisio."Human Leukocyte Antigens and Sister Chromatid Exchanges in Families with Multiple Adenomatosis Coli". *Cancer Detection and Prevention*, 9,459-468,1986.

**Ravagnani F, Sciorelli G**, Rottoli L, Gasparini M, **Pellegris G**. **Supporto granulocitario nei pazienti in trattamento per Linfoma di Burkitt**. Boll Agg di Emaferesi, 3: 38-44, 1987.

**Sciorelli G, Ravagnani F**, Marolda R, Prada A, Villani F, Gambacorti-Passerini C, e Pellegris G. **Immunoterapia adottiva in oncologia**. Boll Agg di Emaferesi, 3: 45-48, 1987.

Prada A, D'Elia E, Manzi R, Perego G, Rizzi M, **Pellegris G, Ravagnani F**, Callegari L, Valente M. **Reinfusione di liquido ascitico. Presentazione di un caso atipico**. Atti dell' XI Congresso Nazionale SICO. Genova, 5-8 Dicembre 1987.

Diotti A, Santoro O, Mantovani L, Regazzoni M, Fontanelli R, **Ravagnani F**, Miotti S, Menard S, Colnaghi MI. **A double determinant radioimmunoassay Mov2-Mov8\* for monitoring ovarians carcinomas: definition of the methodology**. Int J Biol Markers, Vol 2, N° 3: 161-168, 1987.

**Illeni MT, Pellegris G, Sciorelli G, Ravagnani F, Lombardo C**, Maffeo G, Clement MG, Gennari L. **Coltura a breve termine di linfociti di maiale**. Selezione Veterinaria, Vol XXVIII, N°4: 691-694, 1987.

**Sciorelli G, Ravagnani F, Illeni MT, Pellegris G, Lombardo C**, Maffeo G, Clement MG, Gennari L. **Congelamento dei linfociti nel maiale**. Selezione Veterinaria, Vol XXVIII, N°4: 695-698, 1987.

**C.Lombardo**."Prime esperienze sull'uso del Solid Phase nella sierologia piastrinica".Boll. Agg. di Emaferesi, 3, 96-100, 1987.

R.A.Audisio, R.Doci, **C.Lombardo**, **M.T.Illeni**. "Human leukocyteantigens (HLA) and haplotypes in familial polyposis coli (FPC)". *Eur. J.Sur. Oncol.*, 13, 437-440, 1987.

Lanzi C, Banfi P, **Ravagnani F**, and Gambetta RA. **Diversity of effects of two antitumor anthracycline analogs on the pathway of activation of PKC in intact human platelets**. *Biochem*

Pharmacol, 37: 3497-3504, 1988.

Gambacorti-Passerini C, Radrizzani M, Rivoltini L, Marchesi E, **Ravagnani F, Sciorelli G**, Cascinelli N, and Parmiani G. **A new procedure for large scale production and freezing of lymphokine activated killer (LAK) cells to be used in adoptive immunotherapy of cancer.** Tumori, 74: 523-530, 1988.

**Sciorelli G, Ravagnani F**, Gambacorti-Passerini C, Marolda R, Terno G. **Immunoterapia adottiva in oncologia: esperienza personale.** Archivio Casa Sollievo della Sofferenza, 22: 169-175, 1988.

R.A.Audisio, R.Doci, **C.Lombardo, M.T.Illeni.** "HLA Haplotype and Familial Polyposis Coli". Am. J.Gastroenterol., 83 ,460,1988.

Taramelli D., **Mazzocchi A.**, Clemente C., Fossati G., Parmiani G.: **Lack of suppressive activity of human primary melanoma cells on the activation of autologous lymphocytes.** *Cancer Immunol. Immunother.* 26: 61-66, 1988.

Fossati G., Anichini A., Squarcina P., **Mazzocchi A.**, Parmiani G.: **Proliferative and/or cytotoxic activity of lymphocyte clones to autologous human melanoma.** *Int. J. Cancer* 42: 239-245, 1988.

Gianni AM, Bregni M, Siena S, Villa S, **Sciorelli G, Ravagnani F, Pellegris G**, and Bonadonna G. **Rapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high-dose chemo-radiotherapy?** *Hematol Oncol*, 7: 139-148, 1989.

Gambacorti-Passerini C, Rivoltini L, Radrizzani M, Belli F, **Sciorelli G, Ravagnani F**, Galazka AR, Cascinelli N, and Parmiani G. **Differences between in vivo and in vitro activation of cancer patient lymphocytes by Recombinant Interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation.** *Cancer Res*, 49: 5230-5234, 1989.

Siena S, Bregni M, Brando B, **Ravagnani F**, Bonadonna G, and Gianni AM. **Circulation of CD34+ hematopoietic stem cells in the peripheral blood of high-dose Cyclophosphamide-treated patients: enhancement by intravenous Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor.** *Blood*, 74: 1905-1914, 1989.

E.M. Pogliani, **F. Arienti**, G. Corneo: Intravenous infusion of gammaglobulin in adults with chronic refractory immune thrombocytopenic purpura. *Blood*, 74: 886, 1989.

M.Martinetti, C.Tarenzi, L.Salvaneschi, **M.T.Illeni, C.Lombardo**, D.Rovini, M.Placucci, **G.Pellegris.** "Immunoglobulin Allotypes in Familial Malignant Melanoma". *Tumori*, 75, 97-99, 1989.

Anichini A., **Mazzocchi A.**, Fossati G., Parmiani G.: **Cytotoxic T lymphocyte clones from peripheral blood and from tumor site detect intratumor heterogeneity of melanoma cells. Analysis of specificity and mechanisms of interaction.** *J. Immunol.* 142: 3692-3701, 1989.

Siena S, Bregni M, **Ravagnani F**, Brando B, Tarella C, Bonadonna G, and Gianni AM. **Heterogeneity of circulating hematopoietic progenitors in cancer patients treated with high-dose Cyclophosphamide and Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor (RhGM-CSF).** *Hematologica*, Vol 75, Suppl 1: 6-10, 1990.

Bregni M, Siena S, **Ravagnani F**, Bonadonna G, and Gianni AM. **High-dose Cyclophosphamide in patients with operable breast cancer: Recombinant Human GM-CSF ameliorates drug-induced leukopenia and thrombocytopenia.** *Hematologica*, Vol 75, Suppl 1: 95-98, 1990.

**Ravagnani F**, Bregni M, Siena S, Sciorelli G, Gianni AM, and Pellegris G. **Role of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor for large scale collection of peripheral blood stem cells for autologous transplantation.** *Hematologica*, Vol 75, Suppl 1: 22-25, 1990.

Gianni AM, Siena S, Bregni M, Tarella C, Ferrero A, **Ravagnani F**, Stern AC. **Factors influencing the yield of circulating haematopoietic progenitor cells harvested from cancer patients after high-**

**dose Cyclophosphamide treatment, with or without RhGM-CSF infusion.** 16<sup>th</sup> Annual Meeting of the EBMT, The Hague, The Netherlands, May 6-9, 1990.

S. Siena, Bregni M, **Ravagnani F**, Brando B, Bonadonna G, and AM Gianni. **Recombinant Human GM-CSF for Large-Scale Collection of Circulating Hematopoietic Progenitors in Cancer Patients treated with High-Dose Cyclophosphamide.** *Cytokines in Hemopoiesis, Oncology, and AIDS*, 420-5, 1990.

Squadrelli-Saraceno M, Rivoltini L, Cantù G, **Ravagnani F**, Parmiani G. **Local adoptive immunotherapy of advanced head and neck tumors with LAK cells and Interleukin-2.** *Tumori*, 76: 566-571, 1990.

**M.T.Illeni**, D.Rovini, C.Grassi, **C.Lombardo**, M.Placucci, P.Squicciarini, N.Cascinelli, A.Ghidoni. "Sister Chromatid Exchange (SCE) analysis in familial groups of malignant melanoma patients". *Cancer. Genet. Cytogenet.*, 53, 237-246, 1990.

**Mazzocchi A.**, Anichini A., Castelli C., Sensi M., Poli F., Russo C., Parmiani G.: **T lymphocytes can mediate lysis of autologous melanoma cells by multiple mechanisms: evidence with a single T cell clone.** *Cancer Immunol. Immunother.* 32: 13-21, 1990.

**Ravagnani F**, Siena S, Bregni M, **Sciorelli G**, Gianni AM, **Pellegris G.** **Large-scale collection of circulating haematopoietic progenitors in cancer patients treated with high-dose Cyclophosphamide and Recombinant Human GM-CSF.** *Eur J Cancer*, 26: 562-564, 1990

**Ravagnani F**, Siena S, Bregni M, Brando B, Belli N, Lansdorp PM, Notti P, Pellegris G, Gianni AM. **Methodologies to estimate circulating hematopoietic progenitors for autologous transplantation in cancer patients.** *Haematologica*, Vol 76, Suppl 1: 46-49, 1991.

Siena S, Bregni M, Brando B, Belli N, **Ravagnani F**, Gandola L, Stern AC, Lansdorp PM, Bonadonna G, Gianni AM. **Flow cytometry for clinical estimation of circulating hematopoietic progenitors for autologous transplantation in cancer patients.** *Blood*, 77: 400-409, 1991.

L. Rivoltini, G. Cattoretti, **F. Arienti**, A. Mastroianni, C. Melani, M.P. Colombo and G. Parmiani: **The high lysability by LAKs of colon carcinoma cells resistant to Doxorubicin is associated with a high expression of ICAM1, LFA3, NCA and a less-differentiated phenotype.** *Int. J. Cancer*, 47: 746-754, 1991.

S. Spinazze', S. Viviani, P. Bidoli, F. Rovelli, **F. Arienti**, L. Rivoltini, and G. Parmiani: **Effect of prolonged subcutaneous administration of interleukin-2 on the circadian rhythm of cortisol and beta-endorphin in advanced small cell lung cancer patients.** *Tumori*, 77: 496-499, 1991.

**Mazzocchi A.**, Rodolfo M., Parmiani G., Anichini A.: **An autologous T cell clone overcomes intra-melanoma heterogeneity for susceptibility to cell-mediated lysis by using multiple lytic mechanisms: in vitro and in vivo analysis.** *Melanoma Res.* 1: 169-176, 1991.

Sensi M., Castelli C., Anichini A., Grossberger D., **Mazzocchi A.**, Mortarini R., Parmiani G.: **Two autologous melanoma-specific and MHC-restricted human T cell clones with identical intra-tumour reactivity do not share the same TCR V $\alpha$  and V $\beta$  gene families.** *Melanoma Res.* 1: 261-271, 1991.

G. Parmiani, G. Cefalo, L. Rivoltini, **F. Arienti**, M. Gasparini, F. Fossati-Bellani: **Immunoterapia con interleukina-2 ricombinante e linfociti (LAK/TIL) in pazienti affetti da tumori dell'eta' pediatrica.** *Riv. Infettiv. Ped.*, 6: 33-44, 1991.

Siena S, Bregni M, Belli N, **Ravagnani F**, **Notti P**, Magni M, Di Nicola M, Bonadonna G, and Gianni AM. **Practical aspect of flow cytometry to guide large scale collection of circulating hematopoietic progenitors for autologous transplantation in cancer patients.** *Intern J of Cell Cloning*. Vol 10, Suppl 1: 26-29, 1992.

L. Rivoltini, **F. Arienti**, A. Orazi, G. Cefalo, M. Gasparini, C. Gambacorti-Passerini, F. Fossati-Bellani, and G. Parmiani: **Phenotypic and functional analysis of lymphocytes infiltrating pediatric tumors, with**

**a characterization of the tumor phenotype.** *Cancer Immunol. Immunother.*, 34: 241-251, 1992.

**F. Arienti, C. Gambacorti-Passerini, L. Borin, L. Rivoltini, A. Orazi, E.M. Pogliani, G. Corneo, G. Parmiani: Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug-resistance and in the expression of adhesion molecules.** *Ann. Oncol.*, 3:155-162, 1992.

L. Rivoltini, G. Cattoretti, **F. Arienti**, A. Mastroianni and G. Parmiani: **CEA and NCA expressed by colon carcinoma cells affect their interaction with and lysability by activated lymphocytes.** *Int. J. Biol. Markers*; 3: 143-147, 1992.

F. Belli, **F. Arienti**, L. Rivoltini, M. Santinami, L. Mascheroni, A. Prada, M. Ammatuna, E. Marchesi, G. Parmiani, N. Cascinelli, M. Vaglini: **Treatment of recurrent in transit metastases from cutaneous melanoma by isolation perfusion in extra-corporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study.** *Melanoma Res*; 2: 263-271, 1992.

Nistico' P., Mortarini R., De Monte L.B., **Mazzocchi A.**, Mariani M., Malavasi F., Parmiani G., Natali P.G., Anichini A.: **Cell retargeting by bispecific monoclonal antibodies: evidence of bypass of intra-tumor susceptibility to cell lysis in human melanoma.** *J. Clin. Invest.* 90: 1093-1099, 1992.

Castelli C., **Mazzocchi A.**, Salvi S., Anichini A., Sensi M.: **Use of the V $\delta$ 1 variable region in the functional T cell receptor  $\alpha$  chain of a WT31+ cytotoxic T lymphocyte clone which specifically recognizes HLA-A2 molecule.** *Scand. J. Immunol.* 35: 487-494, 1992.

Sensi M., Castelli C., Salvi S., **Mazzocchi A.**, Mortarini R., Nicolini G., Anichini A., Parmiani G.: **Expansion of MHC-restricted anti-melanoma CTL clones with identical T cell receptor from tumor-infiltrating lymphocytes.** *J. Immunother.* 12: 207-211, 1992.

Gasparini M, Rottoli L, Massimino M, Gianni MC, Ballerini E, **Ravagnani F**, Pupa S, Fossati-Bellani F. **Curability of advanced Burkitt's Lymphoma in children by intensive short term chemotherapy.** *Eur J Cancer*, 29: 692-698, 1993.

Bregni M, Siena S, Bonsi L, **Ravagnani F**, Di Nicola M, Peccatori F, Magni M, Bagnara GP, and Gianni AM. **Transplantation of high-dose Cyclophosphamide – and hematopoietic growth factors – elicited peripheral blood progenitors prevents thrombocytopenia after myeloablative cancer therapy.** *L'Osedale Maggiore*, 87 (1): 47-52, 1993.

Gianni AM, Siena S, Bregni M, Di Nicola M, Peccatori F, Magni M, **Ravagnani F**, Sklenar I, and Bonadonna G. **Recombinant human interleukin-3 hastens trilineage hematopoietic recovery following high-dose (7 g/m<sup>2</sup>) Cyclophosphamide cancer therapy.** *Ann Oncol* 4: 759-766, 1993.

Di Nicola M, Siena S, Bregni M, Peccatori F, Magni M, **Ravagnani F**, **Zorzino L**, Bonadonna G, and Gianni AM. **Quantitation of CD34+ peripheral blood hematopoietic progenitors for autografting in cancer patients.** *Int J Artif Organs* 16 S-5: 80-82, 1993.

**G.Pellegris, C.Lombardo**, A.Cantoni, L.Devizzi, M.Balzarotti. **"Study of HLA-DP $\beta$ 1 locus by the Polymerase Chain Reaction technique in patients whit Hodgkin's Disease".** *Tumori*, 79, 133-136, 1993.

**Ravagnani F, Notti P**, Siena S, Bregni M, Zorzino L, Belli N, Gianni AM, and **Pellegris G**. **Clinical application of growth factors for collection of circulating hematopoietic progenitors in breast cancer patients treated with high-dose Cyclophosphamide.** *Int J Artif Organs* 16 S-5: 35-38, 1993.

C. Gambacorti-Passerini, F. Grignani, **F. Arienti**, P.P. Pandolfi, P.G. Pelicci and G. Parmiani: **Human CD4 lymphocytes specifically recognize a peptide representing the fusion of the hybrid protein pml/RAR alpha present in acute promyelocytic leukemia cells.** *Blood*; 5: 1369-1375, 1993.

A. Caraceni, C. Martini, F. Belli, L. Mascheroni, L. Rivoltini, **F. Arienti**, N. Cascinelli: **Neuropsychological and neurophysiological assessment of the central effects of interleukin 2 administration.** *Eur. J. Cancer*; 9: 1266-1269, 1993.

**F. Arienti**, F. Belli, L. Rivoltini, C. Gambacorti-Passerini, L. Furlan, L. Mascheroni, A. Prada, M. Rizzi, E. Marchesi, M. Vaglini, G. Parmiani, N. Cascinelli. **Adoptive immunotherapy of advanced melanoma patients with interleukin-2 (IL-2) and tumor infiltrating lymphocytes (TIL) selected in vitro with low doses of IL-2.** *Cancer Immunol. Immunother.*; 36: 315-322. 1993.

S. Viviani, PM. Salvini, P. Bidoli, E. Camerini, S. Spinazze', **F. Arienti**, L. Rivoltini, V. Motta. **Chronic effects of subcutaneous interleukin-2 therapy on soluble interleukin-2 receptors in advanced small cell lung cancer.** *Int. J. Biol. Markers*; 8, 1: 21-24, 1993.

Anichini A., Maccalli C., Mortarini R., Salvi S., **Mazzocchi A.**, Squarcina P., Herlyn M., Parmiani G.: **Melanoma cells and normal melanocytes share antigens recognized by HLA-A2 restricted cytotoxic T cell clones from melanoma patients.** *J. Exp. Med.* 177: 989-998, 1993.

Sensi M., Salvi S., Castelli C., Maccalli C., **Mazzocchi A.**, Mortarini R., Nicolini G., Herlyn M., Parmiani G., Anichini A.: **T cell receptor (TCR) structure of autologous melanoma-reactive CTL clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR  $\beta$  chain sequence used by an HLA-A2 restricted and melanocyte-lineage-specific CTL clone.** *J. Exp. Med.* 178: 1231-1246, 1993.

C. Melani, C. Chiodoni, **F. Arienti**, C. Maccalli, J. Sule'-Susso, A. Anichini, MP. Colombo, G. Parmiani. Cytokine gene transduction in tumor cells: IL-2 or IL-4 gene transfer in human melanoma cells. *Nat. Immun.*; 13: 76-84, 1994.

L. Rivoltini, **F. Arienti**, F. Belli, N. Cascinelli, G. Parmiani. Adoptive immunotherapy of human melanoma with IL-2 and lymphocytes: results and perspective. In "Cytokine induced tumor immunogenicity: from exogenous molecules to gene therapy", G. Forni, R. Foa', A. Santoni, L. Frati, eds, 365-383, 1994.

N. Cascinelli, R. Foa', G. Parmiani, **F. Arienti**, F. Belli, M.G. Bernengo, C. Clemente, M.P. Colombo, A. Guarini, M.T. Illeni, L. Mascheroni, C. Melani, A. Prada, J. Sule'-Susso. Clinical protocol: active immunization of metastatic melanoma patients with interleukin-4 transduced allogeneic melanoma cells. A phase I-II study. *Hum. Gene Ther.*; 5: 1059-1064, 1994.

**F. Arienti**, J. Sule'-Susso, C. Melani, C. Maccalli, F. Belli, M.T. Illeni, A. Anichini, N. Cascinelli, M.P. Colombo, G. Parmiani. IL-2 gene -transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes. *Hum. Gene Ther.*; 5: 1139-1150, 1994.

Siena S, Bregni M, Di Nicola M, Peccatori F, Magni M, Brando B, **Ravagnani F**, and Gianni AM. **Milan protocol for clinical CD34+ cell estimation in peripheral blood for autografting in patients with cancer.** In « The Hematopoietic Stem Cells: The Mulhouse Manual», Wunder E, Sovalat H, Henon Pr, Serke S (Eds.), AlphaMed Press, Dayton (Publ.): 23-30,1994.

Di Nicola M, Siena S, Bregni M, **Ravagnani F**, Vitello F, Belli N, Magni M, Bonadonna G, and Gianni AM. **Large-scale enrichment of mobilized CD34+ peripheral blood hematopoietic progenitors by removal of nylon wool-adherent mature cells.** *Bone Marrow Transplantation*, 14: 863-869, 1994.

Siena S, Bregni M, Di Nicola M, **Ravagnani F**, Peccatori F, Gandola L, Lombardi F, Tarella C, Bonadonna G, and Gianni AM. **Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors.** *Ann Oncol* 5: 935-941, 1994.

Bregni M, Siena S, Di Nicola M, Doderò, **Ravagnani F**, and Gianni AM. **Mobilizing activity of Recombinant Cytokines after high-dose Cyclophosphamide therapy in cancer patients.** In «Autologous Marrow and Blood Transplantation» Dicke KA and Keating A (Eds) Proceedings of the 7<sup>th</sup>

International Symposium held in Arlington, Texas, August 17-20, 521-526, 1994.

E.Bombardieri, E.Seregni, **C.Lombardo**, A.Cantoni, A.Bogni, C.Botti, L.Sfreddo, I.Cataldo. "**Mucin gene expression in lung cancer tissues**". *Internat. J. Biol. Markers*, 9, 4, 262-263, 1994.

E.Bombardieri, E.Seregni, A.Bogni, C.Botti, L.Maffioli, **C.Lombardo**, A.Cantoni and S.Massarone. "**Lack of tissue specificity of mucin markers in a lung cancer model: biochemical approach**". *Internat. J. of Oncology*, 5, 1363-1367, 1994.

**Mazzocchi A.**, Belli F., Mascheroni L., Vegetti C., Parmiani G., Anichini A.: **Frequency of cytotoxic T lymphocyte precursors (CTLp) interacting with autologous tumor by the T cell receptor: limiting dilution analysis of specific CTLp in peripheral blood and tumor-invaded lymph nodes of melanoma patients**. *Int. J. Cancer* 58: 330-339, 1994.

Bregni M, Siena S, Magni M, Di Nicola M, **Ravagnani F**, and Gianni AM. **Rationale and methods for retroviral-mediated gene transfer into peripheral blood hematopoietic progenitors**. In «Hematopoietic Stem Cells: Biology and Therapeutic Applications» Levitt DJ and Mertelsmann R (Eds), Marcel Dekker, Inc. New York, 185-194, 1995.

Canevari S, Stoter G, **Arienti F**, Bolis G, Colnaghi MI, Di Re EM, Eggermont AMM, Goey SH, Gratama JW, Lamers CHJ, Nooy MA, Parmiani G, Raspagliesi F, **Ravagnani F**, Scarfone G, Trimbos JB, Warnaar SO, and Bolhuis RLH. **Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody**. *J of the National Cancer Institute*, 87, 19: 1463-1469, 1995.

Siena S, Di Nicola M, Bregni M, Mortarini R, Anichini A, Lombardi L, **Ravagnani F**, Parmiani G, and Gianni AM. **Massive ex-vivo generation of functional dendritic cells from mobilized CD34+ peripheral blood progenitors in patients undergoing anticancer therapy**. *Exp Hematol*, 23: 1463-1471, 1995.

Baronzio GF, Solbiati L, Ierace T, Barzaghi F, Suter F, Airoldi M, Belloni G, **Ravagnani F**, **Notti P**, Gramaglia A, Galante F, Livraghi T. **Adjuvant therapy with essential fatty acids (EFAs) for primary liver tumors: some hypotheses**. *Med Hypotheses*, 44: 149-154, 1995.

M. Vaglini, F. Belli, M. Santinami, **F. Arienti**, G. Parmiani, L. Persiani, N. Santoro, M.G. Inglese, F. D'Elia, and N. Cascinelli. Isolation perfusion in extra-corporeal circulation with Interleukin-2 and lymphokine activated killer cells in the treatment of in-transit metastases from limb cutaneous melanoma. *Ann. Surg. Oncol.*; 2(1): 61-70, 1995.

S. Salvi, F. Segalla, S. Rao, **F. Arienti**, M. Sartori, G. Bratina, E. Caronni, A. Anichini, C. Clemente, G. Parmiani, M.L. Sensi. Overexpression of the T-cell receptor beta-chain variable-region TCRBV14 in HLA-A2-matched primary human melanomas. *Cancer Res.*, 55: 3374-3379, 1995.

J. Sule'-Susso, **F. Arienti**, C. Melani, M.P. Colombo, and G. Parmiani. A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes. *Eur. J. Immunol.* 25: 2737-2742, 1995.

C. Melani, J. Sule'-Susso, **F. Arienti**, C. Maccalli, F. Passerini, M.P. Colombo and G. Parmiani. A human melanoma cell line transduced with an interleukin-4 gene by a retroviral vector releases biologically active IL-4 and maintains the original tumor antigenic phenotype. *Hum. Gene Ther.* 6: 1427-1436, 1995.

M. Marchand, P. Weynants, G. Parmiani, **F. Arienti**, F. Belli, N. Cascinelli, E. Rankin, A. Bourlond, R. Vanwijck, Y. Humblet, J.-L. Canon, C. Laurent, J.-M. Naeyaert, R. Plagne, R. Deraemaeker, A. Knuth, E. Jaeger, F. Brasseur, P. Coulie and T. Boon. Tumor regression responses in HLA-A1 melanoma patients treated with a peptide encoded by gene MAGE-3. *Int. J. Cancer* 63; 883-885, 1995

F. Brasseur, D. Rimoldi, D. Lienard, B. Lethe, S. Carrel, **F. Arienti**, L. Suter, R. Vanwijck, A. Bourlond, Y. Humblet, A. Vacca, M. Conese, T. Lahaye, G. Degiovanni, R. Deraemaeker, M. Beauduin, X. Sastre, E.

Salamon, B. Dreno, A. Knuth, C. Chevreau, S. Suci, J.-M. Lachapelle, P. Pouillart, G. Parmiani, F. Lejeune, J.-C. Cerottini, T. Boon and M. Marchand. Expression of MAGE genes in primary and metastatic cutaneous melanoma. *Int. J. Cancer* 63; 375-380, 1995.

Bregni M, Siena S, Di Nicola M, Magni M, Doderio A, Peccatori F, **Ravagnani F**, Danesini G, Laffranchi A, Bonadonna G, and Gianni AM. **Comparative effects of GM-CSF and G-CSF after high-dose Cyclophosphamide cancer therapy.** *J Clin Oncol* 14, 2: 628-635, 1996.

Dermine S, Bertazzoli C, Marchesi E, **Ravagnani F**, Blaser K, Corneo GM, Pogliani E, Parmiani G, and Gambacorti-Passerini C. **Lack of T-cell mediated recognition of the fusion region of the pml/RAR- $\alpha$  hybrid protein by lymphocytes of acute promyelocytic leukemia patients.** *Clin Cancer Res*, 2: 593-600, 1996.

Siena S, Bregni M, Di Nicola M, Magni M, **Ravagnani F**, Gandola L, Lombardi F, Gianni AM. **Ricostituzione ematopoietica a lungo termine dopo terapie antitumorali mieloablative e trapianto di progenitori ematopoietici circolanti.** *Tumori*, Suppl al N° 2: 23-27, 1996.

Di Nicola M, Siena S, Bregni M, Belli N, Milanese M, Ruffini PA, Malaffo F, **Ravagnani F**, and Gianni AM. **Benefits of blood cell transplant cryopreservation with oxypolygelatine (Gelifundol) plasma substitute.** *Bone Marrow Transplant* 18: 619-623, 1996.

Di Nicola M, Bregni, Siena S, Ruffini PA, Milanese M, **Ravagnani F**, and Gianni AM. **Combined negative and positive selection of mobilized CD34+ blood cells.** *British J Haematol* 94: 716-721, 1996.

**Mazzocchi A.**, Storkus W.J., Traversari C., Tarsini P., Maeurer M.J., Rivoltini L., Vegetti C., Belli F., Anichini A., Parmiani G., Castelli C.: **Multiple-melanoma-associated epitopes recognized by HLA-A3-restricted CTLs and shared by melanomas but not melanocytes.** *J. Immunol.* 157: 3030-3038, 1996.

Di Nicola M, Siena S, Corradini P, Bregni M, Milanese M, Magni M, Ruffini PA, **Ravagnani F**, Tarella C, and Gianni AM. **Elimination of bcl-2-IgH-positive follicular lymphoma cells from blood transplants with high recovery of hematopoietic progenitors by the Miltenyi CD34+ cell sorting system.** *Bone Marrow Transplant* 18: 1117-1121, 1996.

E.Seregini, C.Botti, **C.Lombardo**, A.Cantoni, A.Bogni, I.Cataldo and E.Bombardieri. "Pattern of Mucin Gene Expression in Normal and Neoplastic Lung Tissues". *Anticancer Res.* 16, 2209-2214, 1996.

L. Rivoltini, D. J. Loftus, K. Barracchini, **F. Arienti**, **A. Mazzocchi**, W. E. Biddison, M. L. Salgaller, E. Appella, G. Parmiani, and F. Marincola. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. *J. Immunol.*, 156; 3882-3891, 1996.

**F. Arienti**, J. Sule'-Suso, F. Belli, L. Mascheroni, L. Rivoltini, C. Melani, M. Maio, N. Cascinelli, MP. Colombo and G. Parmiani. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. *Hum. Gene Ther.* 7: 1955-1963, 1996.

MA. Player, KC. Barracchini, TB. Simonis, L. Rivoltini, **F. Arienti**, C. Castelli, **A. Mazzocchi**, F. Belli, G. Parmiani and FM. Marincola. Differences in frequency distribution of HLA-A2 subtypes between North American and Italian Caucasian Melanoma patients: relevance for epitope specific vaccination protocols. *J. Immunother.* 19, 357-363, 1996.

Manenti G, De Gregorio L, Pilotti S, Falvella FS, Incarbone M, **Ravagnani F**, Pierotti MA, and Dragani TA. **Association of chromosome 12p genetic polymorphisms with lung adenocarcinoma risk and prognosis.** *Carcinogenesis*, Vol 18, N°10: 1917-1920, 1997.

Bertazzoli C, Marchesi E, Dermine S, **Ravagnani F**, Parmiani G, and Gambacorti-Passerini C. **HLA binding characteristics and generation of cytotoxic lymphocytes against peptides derived from oncogenic proteins.** *Tumori*, 83:847-855, 1997.

Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F, Gandola L, Tarella C, Pileri A, **Ravagnani F**, Valagussa P, and Bonadonna G. **High-dose chemotherapy and autologous bone**

**marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma.** N Engl J Med 336: 1290-1297, 1997.

C. Botti, D.R.M. Negri, E. Seregni, V. Ramakrishna, **F. Arienti**, L. Maffioli, **C. Lombardo**, A. Bogni, C. Pascali, F. Crippa, S. Massaron, F. Remonti, S. Nerini-Molteni, S. Canevari, E. Bombardieri. Comparison of three different methods for radiolabelling of human activated T lymphocytes. Eur. J. Nucl. Med. 24, 497-504, 1997.

F. Belli, **F. Arienti**, J. Sule<sup>3</sup>-Suso, C. Clemente, L. Mascheroni, A. Cattelan, C. Sanantonio, G.F. Gallino, C. Melani, S. Rao, M.P. Colombo, M. Maio, N. Cascinelli, G. Parmiani. **Active immunization of metastatic melanoma patients with interleukin-2 transduced allogeneic melanoma cells: evaluation of efficacy and tolerability.** Cancer Immunol. Immunother. 44, 197-203, 1997.

C.Botti, E.Seregni, **C.Lombardo**, S.Massaron and E.Bombardieri." **Effects of steroid-free serum and steroid supplementation on MUC 1 gene expression in human breast cancer cell line MCF 7**" Anticancer Res., 17, 205-208, 1997.

E.Seregni, C.Botti, S:Massaron, **C:Lombardo**, A:Capobianco, A.Bogni and E.Bombardieri. "**Structure, function and gene expression of epithelial mucins**". Tumori, 83, 625-632, 1997.

E.Seregni, C.Botti, **C.Lombardo**, A.Bonanate, D.Cantarella, E.Bombardieri "**Factor affecting the expression of the epithelial mucin MUC1**". Internal Medicine 5, 147-150, 1997.

C.Botti, E.Seregni, S.Menard, E.Tagliabue, A.Bonanate, D.Cantarella, **C.Lombardo**, S.Massaron, A.Martinetti, L.Ferrari, C.Ghirelli, P.Aiello, E.Bombardieri "**Production of a novel monoclonal antibody against MUC4 mucin**" The Internal Journal of Biological Markers, 12, 42-43, 1997.

Bregni M, Shammah S, Malaffo F, Di Nicola M, Milanese M, Magni M, Matteucci P, **Ravagnani F**, Jordan CT, Siena S, and Gianni AM. **Adenovirus vectors for gene transduction into mobilized blood CD34+ cells.** Gene Therapy, 5: 465-472, 1998.

Bregni M, Di Nicola M, Siena S, Belli N, Milanese M, Shammah S, **Ravagnani F**, Gianni AM. **Mobilized peripheral blood CD34+ cells express more amphotropic retrovirus receptor than bone marrow CD34+ cells.** Haematologica, 83: 204-208, 1998.

L. Rivoltini, D.J. Loftus, P. Squarcina, C. Castelli, F. Rini, **F. Arienti**, F. Belli, F.M. Marincola, C. Geisler, A. Borsatti, E. Appella, G. Parmiani. **Recognition of melanoma-derived antigens by CTL: possible mechanisms involved in down-regulating anti-tumor T-cell reactivity.** Critical Rev. Immunol. 18, 55-63, 1998.

D. J. Hicklin, Z. Wang, **F. Arienti**, L. Rivoltini, G. Parmiani, and S. Ferrone. **b<sub>2</sub>-microglobulin mutations, HLA Class I loss, and tumor progression in melanoma.** J. Clin. Invest. 12, 2720-2729, 1998.

Castelli C., **Mazzocchi A.**, Rini F., Tarsini P., Rivoltini L., Maio M., Gallino G., Belli F., Parmiani G.: **Immunogenicity of the ALLAVGATK (gp100<sub>17-25</sub>) peptide in HLA-A3.1 melanoma patients.** Eur J Immunol., 28: 1143-1154, 1998.

Pende D., Accame L., Pareti L., **Mazzocchi A.**, Moretta A., Parmiani G., Moretta L.: **The susceptibility to natural killer cell-mediated lysis of HLA class I-positive melanomas reflects the expression of insufficient amounts of different HLA class I alleles.** Eur J Immunol., 28: 2384-2394, 1998.

Rivoltini L., Radrizzani M., Accornero P., Squarcina P., Chiodoni C., **Mazzocchi A.**, Castelli C., Tarsini P., Viggiano V., Belli F., Colombo M.P., Parmiani G.: **Human melanoma-reactive CD4+ and CD8+ CTL clones resist FasL-induced apoptosis and use Fas/FasL-independent mechanisms for tumor killing.** J. Immunol. 161: 1220-1230, 1998.

Martinetti A., Seregni E., Belli F., **Mazzocchi A.**, Agresti R., Cascinelli N., Greco M., Bombardieri E.: **Evaluation on serum 2'-5' oligoadenylate synthetase (2'-5' oligoAS) and β<sub>2</sub> microglobulin (B2M) in**

**patients with nodal metastases from cutaneous malignant melanoma treated with rIFN- $\alpha$ 2A.** *Anticancer Res.* 18: 2027-2030, 1998.

Z. Wang, **F. Arienti**, G. Parmiani and S. Ferrone. **Induction and functional characterization of b<sub>2</sub>-m free HLA Class I heavy chains expressed by b<sub>2</sub>-m-deficient cultured melanoma cells FO-1.** *Eur. J. Immunol.* 28, 2817-2826, 1998.

**Ravagnani F**, Siena S, De Reys S, Di Nicola M, **Notti P**, Giardini R, Bregni M, Matteucci P, Gianni AM, and **Pellegris G**. **Improved collection of mobilized CD34+ hematopoietic progenitor cells by a novel automated leukapheresis system.** *Transfusion*, 39: 48-55, 1999.

Castelli C, Tarsini P, **Mazzocchi A**, Rini F, Rivoltini L, **Ravagnani F**, Gallino F, Belli F, and Parmiani G. **Novel HLA-Cw8-restricted T cell epitopes derived from Tyrosinase-Related Protein-2 and gp100 melanoma antigens.** *J Immunol*, 162: 1739-1748, 1999.

Russo A, Eboli M, Pizzetti P, Di Felice G, **Ravagnani F**, Spinelli P, Hotz AM, **Notti P**, Maconi G, Franceschi S, Ferrari D and Bertario L. **Determinants of Helicobacter pylori seroprevalence among Italian blood donors.** *Eur J Gastroent*, 11: 867-73, 1999.

Di Nicola M, Milanese M, Magni M, Bregni M, Carlo-Stella C, Longoni P, Tomanin R, **Ravagnani F**, Scarpa M, Jordan C, Gianni AM. **Recombinant adenoviral vector-lipofectAMINE for gene transduction into human T-lymphocytes.** *Hum Gene Ther*, 10(11): 1875-84, 1999.

Rivoltini L., Squarcina P., Loftus D.J., Castelli C., Tarsini P., **Mazzocchi A.**, Rini F., Viggiano V., Belli F., Parmiani G.: **A superagonist variant of peptide MART-1/Melan A<sub>27-35</sub> elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy.** *Cancer Res.* 59: 301-306, 1999.

M. Marchand, N. van Baren, P. Weynants, V. Brichard, B. Dreno, M.-H. Tessier, E. Rankin, G. Parmiani, **F. Arienti**, Y. Humblet, A. Bourlond, R. Vanwijck, D. Lienard, M. Beauduin, P.-Y. Dietrich, C. Traversari, J. Kerger, G. Masucci, E. Jager, J. De Greve, J. Atzpodien, F. Brasseur, P. G. Coulie, P. van der Bruggen and T. Boon. **Tumor regression observed in metastatic melanoma of patients treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1.** *Int. J. Cancer* 80, 219-230, 1999.

**F. Arienti**, F. Belli, F. Napolitano, J. Sule'-Suso, **A. Mazzocchi**, G. Gallino, A. Cattelan, C. Sanantonio, L. Rivoltini, C. Melani, M.P. Colombo, N. Cascinelli, M. Maio and G. Parmiani. **Vaccination of melanoma patients with IL-4 gene-transduced allogeneic melanoma cells.** *Hum. Gene Ther.* 10, 2907-2916, 1999.

C.Botti, E.Tagliabue, M.Campiglio, **C.Lombardo**, C.Grassi, **G.Pellegris** "Immunosuppression induced by factors of malignant cells promotes cancer growth" *Biologi Italiani*, 9, 30-37, 1999

Bertazzoli C, Marchesi E, Passoni L, Barni R, **Ravagnani F**, **Lombardo C**, Corneo GM, Pioltelli P, Pogliani E, and Gambacorti-Passerini C. **Differential recognition of a BCR/ABL peptide by lymphocytes from normal donors and chronic myeloid leukemia patients.** *Clin Cancer Res*, 6:1931-35, 2000.

Magni M, Di Nicola M, Devizzi L, Matteucci P, Lombardi F, Gandola L, **Ravagnani F**, Giardini R, Dastoli G, Tarella C, Pileri A, and Gianni AM. **Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion.** *Blood*, 96(3): 864-69, 2000.

AJBremers, S.Andreola, E.Leo, F.Gallino, F.Rini, **C.Lombardo**, F.Belli, G.Parmiani, and C.Castelli "T cell responses in colorectal patients: evidence for class II HLA restricted recognition of shared tumor-associated antigens". *Int. J. Cancer.*, 88, 956-961, 2000.

Mecchia M., Matarrese P., Malorni W., D'Agostino G., Sestili P., Santini S.M., Gauzzi M.C., Venditti M., **Mazzocchi A.**, Parmiani G., Belardelli F., Ferrantini M.: **Type I consensus interferon (CIFN) gene**

**transfer into human melanoma cells up-regulates p53 and enhances cisplatin-induced apoptosis: implications for new therapeutic strategies with IFN-alpha.** *Gene Therapy* 7: 167-179, 2000.

Taramelli D, Tognazioli C, **Ravagnani F**, Leopardi O, Giannulis. G, Boelaert JR. **Inhibition of intramacrophage growth of *Penicillium marneffei* by 4-aminoquinolines.** *Antimicrob Agents Chemother*, 45(5): 1450-5, 2001.

Castelli C., Ciupitu A.T., Rini F., Rivoltini L., **Mazzocchi A.**, Kiessling R., Parmiani G. **Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells.** *Cancer Res.* 61: 222-227, 2001.

Parmiani G., Arienti F., Melani C., Belli F., Gallino G., **Mazzocchi A.**: **Gene therapy in melanoma. Melanoma Methods and Protocols**, Vol. 61: 203-220, B. Nickoloff eds; Humana Press, 2001.

Russo A, Maconi G, Spinelli P, Di Felice GD, Eboli M, Andreola S, **Ravagnani F, Settesoldi D, Ferrari D, Lombardo C**, Bertario L. **Effect of lifestyle, smoking, and diet on development of intestinal metaplasia in H. Pylori-positive subjects.** *Am J Gastroenterol*, 96(5): 1402-8, 2001.

**Ravagnani F. Peripheral blood stem cell collection, preparation, and selection.** *Tumori*, 87(2): S38-9, 2001.

**A Mazzocchi, C.Melani, L.Rivoltini, C.Castelli, M.Del Vecchio, C.Lombardo, M.P.Colombo, G.Parmiani** “**Simultaneous transduction of B7.1 and IL-2 genes into human melanoma cells to be used as vaccine: induction of a strong stimulatory activity for autologous and allogenic lymphocytes**”. *Cancer Immunol Immunother.*, 50, 199-211, 2001.

G. Sozzi, D. Conte, L. Mariani, L. Roz, **C. Lombardo**, M.A. Pierotti, L. Tavecchio. “**Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients**” *Cancer Res.* 61, 12, 4675-8, Jun 2001.

**Pellegris G, Ravagnani F, Notti P, Fissi S, Lombardo C. B and C hepatitis viruses, HLA-DQ1 and -DR3 alleles and autoimmunity in patients with hepatocellular carcinoma.** *J Hepatol*, 36(4): 521-6, 2002.

M. Maio, E. Fonsatti, E. Lamaj, M. Altomonte, I. Cattarossi, C. Santantonio, C. Melani, F. Belli, **F. Arienti, M. P. Colombo, G. Parmiani.** **Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells.** *Cancer Immunol. Immunother.* 51, 9-14, 2002.

F. Belli, A. Testori, L. Rivoltini, M. Maio, G. Andreola, M. R. Sertoli, G. Gallino, A. Piris, A. Cattelan, I. Lazzari, M. Carrabba, G. Scita, C. Santantonio, L. Pilla, G. Tragni, C. Lombardo, **F. Arienti, A. Marchiano, F. Bertolini, A. Cova, E. Lamaj, L. Ascani, R. Camerini, M. Corsi, N. Cascinelli, P. K. Srivastava, J. J. Lewis and G. Parmiani.** **Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein peptide-complex-96 (Oncophage): clinical and immunological findings.** *J. Clin. Oncol.* 15, 4139-4140, 2002.

M. Rodolfo, R. Luksch, E. Stockert, Y. Chen, P. Collini, T. Ranzani, **C. Lombardo**, P. Dalerba, L. Rivoltini, **F. Arienti, F. Fossati-Bellani, L. J. Old, G. Parmiani and C. Castelli.** **Antigen specific immunity in neuroblastoma patients: antibody and T cell recognition of NY-ESO-1 tumor antigen.** *Cancer Res.* 15, 6948-6955, 2003

Novellino L., Renkvist N., Rini F., **Mazzocchi A.**, Rivoltini L., Greco A., Deho P., Squarcina P., Robbins P.F., Parmiani G., Castelli C. **Identification of a mutated receptor-like protein tyrosine phosphatase k as a novel, class II HLA-restricted melanoma antigen.** *J. Immunol.* 170: 6363-6370, 2003.

P. Dalerba, **A. Mazzocchi**, I. Cigola, C. Casati, T. Schweieighoffer, **C. Lombardo**, F. Belli, G. Gallino, E. Leo, C. Castelli “**Class-I loss in colorectal cancer: identification of complex phenotypes due to the simultaneous occurrence of multiple genetic defects**” *Basic Research*; 9: 202-9, 2003

Mortarini R, Piris A, Maurichi A, Molla A, Bersani I, Bono A, Bartoli C, Santinami M, **Lombardo C**,

**Ravagnani F, Cascinelli N, Parmiani G, Anichini A. Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma. Cancer Res, 63(10): 2535-45, 2003.**

Russo A, Maconi G, **Lombardo C, Settesoldi D, Ferrari D, Ravagnani F**, Andreola S, Pizzetti P, Spinelli P, Bertario L. **Human leukocyte antigen class II genes and Helicobacter pylori infection: does genotype overwhelm environmental exposure?** Nutrition, 19(9): 708-15, 2003.

Di Nicola M, Carlo-Stella C, Anichini A, Mortarini R, Guidetti A, Tragni G, Gallino F, Del Vecchio M, **Ravagnani F**, Morelli D, Chaplin P, Arndtz N, Setter G, Drexler I, Parmiani G, Cascinelli N, Gianni AM. **Clinical protocol: immunization of patients with malignant melanoma with autologous CD34(+) cell-derived dendritic cellstransduced ex vivo with recombinant replication-deficient vaccinia vector encoding the human tyrosinase gene: a phase I trial.** Hum Gene Ther, 14(14): 1347-60, 2003.

Basilico N, Tognazioli C, Picot S, **Ravagnani F**, Taramelli D. **Synergistic and antagonistic interactions between haemozoin and bacter endotoxin on human and mouse macrophages.** Parassitologia, 45(3-4): 135-40, 2003.

Luksch F, Perotti D, Cefalo G, Gambacorti Passerini C, Massimino M, Spreafico F, Casanova M, Ferrari A, Terenziani M, Polastri D, Gambirasio F, Podda M, Bozzi F, **Ravagnani F**, Permiani G, Fossati Bellani F. **Immunomodulation in a treatment program includine pre and post-operative Interleukin-2 and chemotherapy for childhood osteosarcoma.** Tumori, 89(3): 263-8, 2003.

Carlo-Stella C, Di Nicola M, Milani R, Guidetti A, Magni M, Milanese M, Longoni P, Matteucci P, Formelli F, **Ravagnani F**, Corradini P, Gianni AM. **Use of recombinant Human Growth Hormone (rhGH) plus Recombinant Human Granulocyte Colony-Stimulating Factor (rhG-CSF) for the mobilization and collection of CD34+ cells in poor mobilizer.** Blood, May 1;103(9): 3287-95, 2004.

Spinola M, Conti B, **Ravagnani F**, Fabbri A, Incarbone M, Cataldo I, Pira E, Pelucchi C, La Vecchia C, Dragani TA. **A new polymorphism (Ser362Thr) of the L-myc gene is not associated with lung adenocarcinoma risk and prognosis.** Eur J Cancer Prev. 13(1): 87-9, 2004.

Di Nicola M, Carlo-Stella C, Mortarini R, Baldassari P, Guidetti A, Gallino GF, Del Vecchio M, **Ravagnani F**, Magni M, Chaplin P, Cascinelli N, Parmiani G, Gianni AM, Anichini A. **Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma.** Clin Cancer Res. 15;10(16): 5381-90, 2004.

Perotti D, De Vecchi G, Testi MA, Lualdi E, Modena P, Mondini P, **Ravagnani F**, Collini P, Di Renzo F, Spreafico F, Terenziani M, Sozzi G, Fossati-Bellani F, Radice P. **Germline mutations of POU6F2 gene in Wilms tumors with loss of heterozygosity on chromosome 7p14.** Hum Mutat. 24(5): 400-7, 2004.

D. Tosi, R. Valenti, A. Cova, G. Sovena, V. Huber, L. Pilla, F. **Arienti, F.** Belardinelli, G. Parmiani and L. Rivoltini. Role of cross-talk between IFN- $\alpha$ -induced monocyte-derived dendritic cells and NK cells in priming CD8+ T cell responses against human tumor antigens. J. Immunology 172: 5363-5370, 2004

Massimino L, Gandola L, Luksch R, Spreafico F, Riva D, Solero C, Giangaspero F, Locatelli F, Podda M, Bozzi F, Pignoli E, Collini P, Cefalo G, Zecca M, Casanova M, Ferrari A, Terenziani M, Meazza C, Polastri D, Scaramazza D, **Ravagnani F**, Fossati-Bellani F. **Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma.** Neuro-oncol. 7(1): 41-8, 2005.

Luksch R, Podda M, Gandola L, Polastri D, Piva L, Castellani R, Collini P, Massimino M, Cefalo G, Terenziani M, Ferrari A, Casanova M, Spreafico F, Meazza C, Bozzi F, Marchianò A, **Ravagnani F**, Fossati-Bellani F. **Stage 4 neuroblastoma: sequential hemi-body irradiation or high-dose chemotherapy plus autologous haematopoietic stem cell transplantation to consolidate primary treatment.** Br J Cancer. 6; 92(11): 1984-8, 2005.

Spinola M, Leoni VP, Tanuma J, Pettinicchio A, Frattini M, Signoroni S, Agresti R, Giovanazzi R, Pilotti S, Bertario L, **Ravagnani F**, Dragani TA. **FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer.** Oncol Rep. 14(2): 415-9, 2005.

P. Dalerba, C. Guiducci, P.L. Pollini, I. Cigola, M. Parenza, M. Frattini, G. Gallino, I. Carnevali, I. Di Giulio, S. Andreola, **C. Lombardo**, L. Rivoltini, T. Schweighoffer, F. Belli, M.P. Colombo, G. Permiani and C. Castelli **“Reconstitution of Human Telomerase Transcriptase Expression Rescues Colorectal Carcinoma Cells from in vitro Senescence: Evidence against Immortalità as a Constitutive Trait of Tumor Cells”** Cancer res 2005; 65: (6) March 15, 2005

Spinola M, Leoni V, Pignatiello C, **Ravagnani F**, Pastorino U, Dragani TA. **The functional FGFR4 Gly388Arg Polymorphism predicts prognosis in lung adenocarcinoma patients.** J Clin Oncol. 10; 23(29): 7307-11, 2005.

Massimino M, Gandola L, Spreafico F, Luksch R, Collini P, Giangaspero F, Simonetti F, Casanova M, Cefalo G, Pignoli E, Ferrari A, Terenziani M, Podda M, Meazza C, Polastri D, Poggi G, **Ravagnani F**, Fossati-Bellani F. **Supratentorial primitive neuroectodermal tumors (S-PNET) in children: A prospective experience with adjuvant intensive chemotherapy and hyperfractionated accelerated radiotherapy.** Int J radiat Oncol Biol Phys 64(4): 1031-7, 2006.

Manenti G, Galbiati F, Pettinicchio A, Spinola M, Piconese S, Leoni VP, Conti B, **Ravagnani F**, In carbone M, Pastorini U, Dragani TA. **A VL141L polymorphism of the human LRMP gene is associated with survival of lung cancer patients.** Carcinogenesis 27(7): 1386-90, 2006.

T. Di Pucchio, L. Pilla, I. Capone, M. Ferrantini, E. Montefiore, F. Urbani, R. Patuzzo, E. Pennacchioli, M. Santinami, A. Cova, G. Sovena, **F. Arienti, C. Lombardo**, A. Lombardi, P. Caporaso, S. D’Atri, P. Marchetti, E. Bonmassar, G. Parmiani, F. Belardelli, L. Rivoltini. **Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8+T cells and monocytes/dendritic cell-precursors.** Cancer Res, 66: 4943-4951, 2006

A. Contadini, M. Testi, M. Cuccia, M. Martinetti, C. Carcassi, A. Chiesa, E. Casentini, E. Dametto, S. Frison, A. Iannone, **C. Lombardo**, A. Malagoli, M. Mariani, L. Mariotti, L. Mascaretti, L. Mele, V. Miotti, S. Nesci, G. Ozzella, D. Piancatelli, G. Romeo, C. Tagliaferro, S. Vatta, M. Andreani, R. Conte **“Distribution of killer cell immunoglobulin-like receptors genes in the Italian Caucasian population “** J Transl Med. 2006, Oct 27; 4 :

L. Moranti, D. Ferrari, **C. Lombardo**, A. Pession, G. Tallini **“Monitoring HCV RNA viral load by locked nucleic acid molecular beacons real time PCR”** J Virol Methods. Dec 14; 2006,

L. Pilla, R. Patuzzo, L. Rivoltini, M. Maio, E. Pennacchioli, E. Lamaj, A. Maurichi, S. Massarut, A. Marchiano, C. Santantonio, D. Tosi, **F. Arienti**, A. Cova, G. Sovena, A. Piris, D. Nonaka, I. Bersani, A. Di Florio, PK. Srivastava, A. Hoos, M. Santinami, G. Parmiani. **A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon- $\alpha$  in metastatic melanoma patients.** Cancer Immunol Immunother 55: 958-968, 2006

C. Casati, C. Camisaschi, F. Rini, **F. Arienti**, L. Rivoltini, F. Triebel, G. Parmiani and C. Castelli. **Soluble Human LAG-3 molecule amplifies the in vitro generation of type 1 tumor-specific immunity.** Cancer Res. 66, 4450-4460, 2006

**F. Ravagnani, P. Coluccia**, P. Notti, **F. Arienti, A. Bompadre, M. Avella**, F. Bozzi, M. Barzano, M.G. Podda, A. Pupa, R. Luksch: **Peripheral blood stem cell collection in pediatric patients. Feasibility of leukapheresis under anesthesia in uncompliant small children with solid tumors.** J Clin Apher 21: 85-91, 2006.

Spinola M, Leoni VP, Galvan A, Korsching E, Conti B, Pastorino U, **Ravagnani F**, Columbano A, Skaug V, Haugen A, Dragani TA. **Genome-wide single nucleotide polymorphism analysis of lung cancer risk detects the KLF6 gene.** Cancer Lett Jan 12, 2007

M. Daniotti, V. Vallacchi, L. Rivoltini, R. Patuzzo, M. Santinami, **F. Arienti**, M. A. Pierotti, G. Parmiani, M. Rodolfo: **Detection of mutated BRAFV600E variant in circulating DNA of stage III-IV melanoma patients.** Int J Cancer 120(11): 2439-44, 2007

De Vecchi G, Verderio P, Pizzamiglio S, Manoukian S, Barile M, Fortuzzi S, **Ravagnani F**, Pierotti MA, Radice P, Peterlongo P. **Evidences for association of the CASP8 -652 6N del promoter polymorphism with age at diagnosis in familial breast cancer cases.** Breast Cancer Res Treat. 2008; 32(2): 140-3.

Casati C., Camisaschi C., Novellino L., **Mazzocchi A.**, Triebel F., Rivoltini L., Permiani G., Castelli C. **Human Lymphocyte Activation Gene-3 molecules expressed by activated T cells deliver costimulation signal for dendritic cells activation** *J. Immunol.* 180: 3782-3788, 2008.

C, Maccalli, V. Di Cristanziano, V. Fodale, D. Corsi, G. D'Agostino, V. Petrangeli, L. Laurenti, S. Guida, A. **Mazzocchi, F. Arienti**, M. P. Perrone, C. Castelli, L. Rivoltini, V. Zagonel, M. Tartaglia, G. Parmiani and F. Belardelli. **Induction of Both CD8+ and CD4+ T-Cell Mediated Responses in Colorectal Cancer Patients by Colon Antigen-1.** Clin Cancer Res 14(22), 2008

A. De Filippo, R.J. Binder, C. Camisaschi, V. Beretta, **F. Arienti**, A. Villa, P. Della Mina, G. Parmiani, L. Rivoltini, C. Castelli. **Human plasmacytoid dendritic cells interact with gp96 via CD91 and regulate inflammatory responses.** J Immunol. 181(9):6525-35, 2008.

Massimino M, Gandola L, Spreafico F, Biassoni V, Luksch R, Collini P, Solero CN, Simonetti F, Pignoli E, Cefalo G, Poggi G, Modena P, Mariani L, Potepan P, Podda M, Casanova M, Pecori E, Acerno S, Ferrari A, Terenziani M, Meazza C, Polastra D, **Ravagnani F**, Fossati-Bellani F. **No salvage using high-dose chemotherapy plus/minus reirradiation for relapsing previously irradiated medulloblastoma.** Int J Radiat Oncol Biol Phys. 2008 Nov 17.

Di Nicola M, Zappasodi R, Carlo-Stella C, Mortarini R, Pupa SM, Magni M, Devizzi L, Matteucci P, Baldassari P, **Ravagnani F**, Cabras A, Anichini A, Gianni AM. **Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic response in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.** Blood 2009 Jan 1; 113(1): 18-27.

A. Doderò, C. Carniti, A. Raganato, A. Vendramin, L. Farina, F. Spina, C. Carlo-Stella, S. Di Terlizzi, M. Milanese, P. Longoni, L. Gandola, **C. Lombardo**, P. Corradini **"Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusion contribute to improve T-cell recovery"** Blood., May 7; 113 (19) : 4771-4779; 2009.

A. Doderò, C. Carniti, A. Raganato, A. Vendramin, L. Farina, F. Spina, C. Carlo-Stella, S. Di Terlizzi, M. Milanese, P. Longoni, L. Gandola, **C. Lombardo**, P. Corradini **"Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusion contribute to improve T-cell recovery"** Blood., May 7; 113 (19) : 4771-4779; 2009.

Catucci I, Verderio P, Pizzamiglio S, Manoukian S, Peissel B, Barile M, Tizzoni L, Bernard L, **Ravagnani F**, Galastri L, Pierotti MA, Radice P, Peterlongo P. Letter to the editor: **SNPs in ultraconserved elements and familial breast cancer risk.** Carcinogenesis. 2009 Jan 6.

Mortarini R, Vegetti C, Molla A, Arienti F, **Ravagnani F**, Maurichi A, Patuzzo R, Santinami M, Anichini A. Impaired STAT phosphorylation in T cells from melanoma patients in response to IL-2: association with clinical stage. Clin Cancer Res. 2009 Jun 15;15(12):4085-94.

**Coluccia P**, Montefusco V, Tunesi S, **Avella M, Bompadre A**, Longoni P, Milanese M, De Carli A, **Ravagnani F**. **Peripheral blood stem cell collection in multiple myeloma: a retrospective analysis of six years leukapheresis activity in 109 patients treated at Istituto Nazionale dei Tumori of Milan.** J Clin Apher. 2009; 24(4): 134-40.

Perseghin P, Terruzzi E, Dassi M, Baldini V, Parma M, **Coluccia P**, Accorsi P, Confalonieri G, Tavecchia L, Verga L, **Ravagnani F**, Iacone A, Pogliani EM, Pioltelli P. **Management of poor peripheral blood stem cell mobilization: Incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions.** Transfus Apher Sci. 2009 Aug; 41(1): 33-7.

Basilico N, Parapini S, Sisto F, Omodeo-Salè F, Coghi P, **Ravagnani F**, Olliario P, Taramelli D. **The lipid**

**moiety of haemozoin (Malaria Pigment) and P. Falciparum parasitized red blood cells bind synthetic and native endothelin-1.** J Biomed Biotechnol. 2010; 2010:854927. Epub 2010 Feb 24.

Nicoloso MS, Sun H, Spizzo R, Kim H, Wickramasinghe P, Shimizu M, Wojcik SE, Ferdin J, Kunej T, Xiao L, Manoukian S, Secreto G, **Ravagnani F**, Wang X, Radice P, Croce CM, Dayaluri RV, Calin GA. **Single-nucleotide polymorphism inside microRNA target sites influence tumor susceptibility.** Cancer Res. 2010 Apr 1;70(7):2789-98.

Anichini A, Molla A, Vegetti C, Bersani I, Zappasodi R, Arienti F, **Ravagnani F**, Maurichi A, Patuzzo R, Santinami M, Pircher H, Di Nicola M, Mortarini R. **Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma.** Cancer Res. 2010 Nov 1;70(21):8378-87.

Peterlongo P, Caleca L, Cattaneo E, **Ravagnani F**, Bianchi T, Galastri L, Bernard L, Ficarazzi F, Dall'olio V, Marme F, Langheinze A, Sohn C, Burwinkel B, Giles GG, Baglietto L, Severi G, Odefrey FA, Southey MC, Osorio A, Fernández F, Alonso MR, Benítez J, Barile M, Peissel B, Manoukian S, Radice P. **The rs12975333 variant in the miR-125a and breast cancer risk in Germany, Italy, Australia and Spain.** J Med Genet. 2011 Oct;48(10):703-4.

Catucci I, Verderio P, Pizzamiglio S, Bernard L, Dall'olio V, Sardella D, **Ravagnani F**, Galastri L, Barile M, Peissel B, Zaffaroni D, Manoukian S, Radice P, Peterlongo P. **The SNP rs895819 in miR-27a is not associated with familial breast cancer risk in Italians.** Breast Cancer Res Treat. 2012 Jun;133(2):805-7.

Magni M, Nicola MD, Carlo-Stella C, Matteucci P, Devizzi L, Guidetti A, Ravagnani F, Gianni AM. **Detection of minimal residual disease in hematopoietic progenitor cell harvests: lack of predictive value of peripheral blood and bone marrow analysis in mantle cell and indolent lymphoma.** Am J Blood Res. 2012;2(2):105-12.

Filipazzi P, Pilla L, Mariani L, Patuzzo R, Castelli C, Camisaschi C, Maurichi A, Cova A, Rigamonti G, Giardino F, Di Florio A, Asioli M, Frati P, Sovena G, Squarcina P, Maio M, Danielli R, Chiarion-Sileni V, Villa A, **Lombardo C**, Tragni G, Santinami M, Parmiani G, Rivoltini L.P. **“ Limited Induction of Tumor – cross- reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen-Class I-Modified Peptides”** Clin Cancer Res, pulisce on line, First October, 2012;

Milazzo L., Corbellino M., Foschi A., Micheli V., Doderò A., **Mazzocchi A.**, Montefusco V., Zehender G., Antinori S. **Late onset of HBV reactivation following hematopoietic stem cell transplantation: successful treatment with combined entecavir plus tenofovir therapy.** *Transpl Infect Dis.* 14: 95-98, 2012.

**Coluccia P**, Crovetto G, Del Fante C, Dallavalle FM, Laszlo D, Ferremi P, Marenchino D, Santoleri L, De Filippo C, Mattana F, Mariani L, Perseghin P, **Ravagnani F**. **Screening of related donors and peripheral blood stem cell collection practices at different Italian apheresis centres.** Blood Transfus. 2012 Jul 12:1-8.

